openPR Logo
Press release

SuppreMol employs Protagen biomarkers in SLE study

08-03-2011 07:54 AM CET | Health & Medicine

Press release from: SuppreMol GmbH

/ PR Agency: akampion
Munich and Dortmund, Germany, August 2, 2011. SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases and allergies, and Protagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis, today announced a collaboration to identify therapy-related biomarkers in patients with Systemic Lupus Erythematosus (SLE).

“We will use the unique biomarker portfolio of Protagen for the rapid identification of autoantibody signatures in the serum of SLE patients enrolled in our current phase IIa study of our lead product SM101,“ said Prof. Peter Buckel, CEO of SuppreMol. „With these signatures we aim to identify patients who are most likely to respond favorable to SM101. In addition, our findings may allow the classification of patients into subgroups as SLE is a disease with very diverse manifestations. The UNIarray® technology platform of Protagen offers a unique opportunity to explore the potential for a personalized SLE therapy concomitant to the clinical development of SM101.”

“SuppreMol is the first innovative clinical stage company building on the early integration of our indication-specific biomarker panels at the beginning of Phase IIa. We are very happy to enter into this collaboration project. Both of our companies are convinced that this approach will allow for specific enrollment as well as better stratification of SLE patients, and that it will significantly reduce the development risks of upcoming clinical studies,“ added Dr. Stefan Müllner, CEO of Protagen.

Financial details of the collaboration are not disclosed. The cooperation as well as SuppreMol’s phase IIa SLE study are supported by the German Federal Ministry for Education and Research (BMBF) as part of the Leading Edge Cluster m4.

###

About SuppreMol

SuppreMol is a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases and allergies. The company is pioneering the development of soluble Fc gamma receptors (sFcgammaRs), which are recombinant autologous therapeutic proteins with a proven, strong immunosuppressive potential. The company plans to develop sFcgammaRs for the treatment of Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) and other autoimmune conditions. SuppreMol’s pipeline comprises three early antibody development programs against Fcg receptor IIb (FcgRIIb) suitable for alternative treatment strategies and indications (e.g. hypersensitivities) as well as an anti IL-3 antibody to treat RA for which the company obtained an exclusive license option recently.

SuppreMol was founded in 2002 as a spin-off from the laboratory of Prof. Dr. Robert Huber, Nobel Prize for Chemistry in 1988, at the Max Planck Institute for Biochemistry in Martinsried, Germany. The company has raised EUR 35.2 million in three financing rounds since May 2006 and investors include MIG AG, BioMedPartners AG, Santo Holding GmbH, FCP Biotech Holding GmbH as well as KfW Mittelstandsbank, Bayern Kapital GmbH, Max Planck Society, and Z-Cube. SuppreMol received BMBF research grants of over EUR 2 million since 2007.

Contact

Prof. Dr. Peter Buckel
CEO
SuppreMol GmbH
Am Klopferspitz 19
82152 Martinsried / Munich

Tel: +49 (0) 89 30 90 50 680
Fax: +49 (0) 89 30 90 50 68 68
e-Mail: info@suppremol.com
www.suppremol.com

Media Inquiries

Dr. Ludger Wess
Managing Partner
akampion
Hasenhoehe 29
22587 Hamburg/Germany

Tel: +49 (0) 40 88 16 59 64
Fax: +49 (0) 40 88 16 59 65
e-Mail: ludger@akampion.com
www.akampion.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SuppreMol employs Protagen biomarkers in SLE study here

News-ID: 185946 • Views: 979

More Releases for SLE

Global Systemic Lupus Erythematosus (SLE) Medication Market Expected to Witness …
LP INFORMATION recently released a research report on the Systemic Lupus Erythematosus (SLE) Medication market analysis, which studies the Electrical Cord Reels's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global “Systemic Lupus Erythematosus (SLE) Medication Market 2020-2025” Research Report categorizes the global Systemic Lupus Erythematosus (SLE) Medication market by key players, product type, applications and regions,etc. The report also covers
Systemic lupus erythematosus (SLE) Market - Global Industry Analysis 2017 - 2025
Systemic lupus erythematosus (lupus) is an autoimmune disease which is characterized by inflammation of tissue in the body. Immune response is directed toward the body’s own cells, resulting in acute or chronic inflammation. Symptoms of lupus are general and hence often mistaken with symptoms of other diseases. This results in unnoticed progression of disease in the body. The disease is more common in women and usually affects individuals in the
Systemic lupus erythematosus (SLE) Market Research Report : Forecast 2025
In terms of geography, North America accounts for the dominant share in terms of revenue owing to advancements in the treatment of systemic lupus erythematosus and rising awareness among people about the disease. Europe accounts for the second largest market in terms of revenue due to high incidence rate of SLE and increase in research activities in the field of systemic lupus erythematosus. The Asia Pacific market is also witnessing
Global Resuscitation Ventilators Market 2017 : Eternity, SIRIUSMED, Siare & SLE
The survey report by Market Research Store is an overview of the global Resuscitation Ventilators market. It covers all the recent trends including key developments in the global market in present and in future. Analyses of the global Resuscitation Ventilators market trends along with the projections of CAGRs (compound annual growth rates) are provided in the research report. Further, an evaluation of the history of the global market and the basic
Global Respiratory Devices Market-SLE Ltd, Teijin Pharma, Resmed, Weinmann
Global Respiratory Devices Market report 2017 is an in-depth research on the current situation of the Respiratory Devices industry. The Scope of the Respiratory Devices research report: The Global Respiratory Devices Market primarily includes a basic overview of the Respiratory Devices industry. It also includes Respiratory Devices definitions, classifications and applications. It segments the market by applications, types, regions, competitive players and also analyzes Respiratory Devices market size, business share and Respiratory
Systemic Lupus Erythematous SLE Drugs Market To Increase at Steady Growth Rate
Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis,